Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 112

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 112
---
 net cash of $0.6 million was used in our operating activities. As of December 31, 2024 and December 31, 2023, we had
a negative working capital of $5.5 million and $2.8 million, respectively, and an accumulated deficit of approximately
$41.7 million and $46.9 million, respectively. As of December 31, 2024, our cash and cash equivalents totaled approximately
$0.2 million. We believe that after the completion of this offering our cash and cash equivalents, including the proceeds from
this offering, will enable us to fund our operations through March 31, 2027.

Through December 31, 2024,
we have financed our operations primarily through private placements, convertible loans and short-term loans. Total invested capital
as of December 31, 2024 was $35.7 million, which included Ordinary Shares, Preferred Shares and warrants to purchase Preferred Shares.

The following table summarizes
our statement of cash flows for the years ended December 31, 2024 and 2023:

|                                                  | (U.S. dollars in thousands except share and per share data) | For the Years Ended 
 December            
 31,                 | 2024 |   |     |     |   2023 |   |
|:-------------------------------------------------|:------------------------------------------------------------|:--------------------|-----:|:--|:----|:----|-------:|:--|
| Net cash used in operating activities            |                                                             | $                   | (641 | ) |     |     | (1,220 |   |
| Net cash used in investing activities            |                                                             |                     |    - |   |     |     |      - |   |
| Net cash provided by financing activities        |                                                             |                     |  525 |   |     |     |    325 |   |
| (Decrease) Increase in cash and cash equivalents |                                                             | $                   | (116 | ) |     |     |   (895 | ) |

<div align='center'>66</div>

Net cash used in operating activities

Net cash provided by (used in) operating activities

Net cash used in operating
activities for the year ended December 31, 2024 was $0.6 million, compared to $1.2 million for in 2023. This decrease is mainly due to
receipt of approval from EASME in April 2024.

Net cash used in investing activities